GlassScriptPhysician profile
Sheila M Burick
NPI 1831172469
$3,563.47
in general payments reported to CMS, 2019-2025
34 companies · $701 in 2025
The $701 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,280 · 2020: $52.12 · 2021: $223 · 2022: $232 · 2023: $241 · 2024: $834 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,776.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $453.53 | 2019-2023 | Wegovy |
| Lilly USA, LLC | $255.55 | 2019-2025 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $248.84 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $223.26 | 2019-2021 | |
| Amgen INC. | $200.92 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.23 | 2019-2024 | Jardiance |
| Pfizer INC. | $136.70 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $134.83 | 2024 | |
| Sunovion Pharmaceuticals INC. | $130.25 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2024 | Caplyta |
| Exact Sciences Corporation | $119.39 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $117.61 | 2025 | |
| Inspire Medical Systems, INC. | $113.41 | 2025 | Inspire |
| Alkermes, INC. | $110.43 | 2024 | Lybalvi, Vivitrol |
| Merck Sharp & Dohme LLC | $108.57 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $100.43 | 2019-2020 | |
| Braeburn INC. | $88.98 | 2025 | Brixadi |
| Regeneron Healthcare Solutions, INC. | $85.14 | 2024 | Dupixent |
| Mylan Specialty L.P. | $84.50 | 2024 | Yupelri |
| Abbvie INC. | $83.84 | 2019-2024 | |
| Genzyme Corporation | $78.21 | 2021 | |
| Novartis Pharmaceuticals Corporation | $60.12 | 2023 | |
| Corcept Therapeutics | $50.94 | 2019 | |
| Abbott Laboratories | $48.43 | 2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.04 | 2019 | |
| Idorsia Pharmaceuticals US INC | $30.22 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $28.23 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.20 | 2019 | |
| Celgene Corporation | $18.94 | 2019 | |
| Neuronetics, INC. | $17.32 | 2019 | |
| Axsome Therapeutics, INC. | $17.24 | 2025 | Auvelity |
| Biogen, INC. | $16.76 | 2019 | |
| Astellas Pharma US INC | $16.60 | 2019 | |
| Amarin Pharma, INC. | $14.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Burick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.